Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Heidelberg Pharma AG    WL6   DE000A11QVV0

HEIDELBERG PHARMA AG (WL6)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 07/17 09:30:00 pm
2.755 EUR   +0.55%
07/12HEIDELBERG PHAR : reports on first half-year
EQ
07/09HEIDELBERG PHAR : half-yearly earnings release
06/26HEIDELBERG PHAR : Heidelberg Pharma Reports Outcome Of Annual Genera..
EQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
2.75(c) 2.745(c) 2.76(c) 2.74(c) 2.74 Last
9 608 2 218 0 2 900 0 Volume
-1.43% -0.18% +0.55% -0.72% 0.00% Change
More quotes
Financials (EUR)
Sales 2018 4,00 M
EBIT 2018 -12,9 M
Net income 2018 -12,0 M
Finance 2018 31,6 M
Yield 2018 -
Sales 2019 4,20 M
EBIT 2019 -12,7 M
Net income 2019 -12,8 M
Finance 2019 18,8 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 11,5x
EV / Sales2019 14,0x
Capitalization 77,6 M
More Financials
Company
Heidelberg Pharma AG engages in the development of diagnostic and therapeutic products for the detection and targeted treatment of various types of cancer.It operates through the following segments: Customer Specific Research (Cx), Diagnostics (Dx), andTherapeutics (Rx).The Customer Specific... 
More about the company
Surperformance© ratings of Heidelberg Pharma AG
Trading Rating : Investor Rating :
More Ratings
Latest news on HEIDELBERG PHARMA AG
07/12HEIDELBERG PHARMA : reports on first half-year
EQ
07/09HEIDELBERG PHARMA AG : half-yearly earnings release
06/26HEIDELBERG PHARMA AG : Heidelberg Pharma Reports Outcome Of Annual General Meeti..
EQ
05/30HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
04/30HEIDELBERG PHARMA AG : Heidelberg Pharma Presents at Upcoming Conferences and In..
EQ
04/30HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
04/12HEIDELBERG PHARMA AG : Interim Management Statement on the First Three Months of..
EQ
04/09HEIDELBERG PHARMA : Presents Proprietary ATAC Technology Platform at Two Scienti..
EQ
03/29HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
03/22HEIDELBERG PHARMA AG : Heidelberg Pharma announces financial figures for fiscal ..
EQ
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2017WILEX AG successfully completes change of name to Heidelberg Pharma AG  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX : Announces Adjustment of Guidance  
More tweets
Qtime:31
News from SeekingAlpha
2016Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target 
Chart HEIDELBERG PHARMA AG
Duration : Period :
Heidelberg Pharma AG Technical Analysis Chart | WL6 | DE000A11QVV0 | 4-Traders
Technical analysis trends HEIDELBERG PHARMA AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,25 €
Spread / Average Target 55%
EPS Revisions
Managers
NameTitle
Jan Schmidt-Brand Chief Executive Officer & Chief Financial Officer
Christof Hettich Chairman-Supervisory Board
Andreas Pahl Head-Research & Development
Friedrich von Bohlen und Halbach Member-Supervisory Board
Georg F. Baur Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HEIDELBERG PHARMA AG-15.67%91
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC10.00%22 131
LONZA GROUP9.53%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147